1 recruiting. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Recruiting 1 |
Follow TS-104: new trials by email Literature Review of TS-104 trials Research Report on TS-104
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a Monotherapy in Subjects With Select Advanced Solid Tumors TS-104 - NSCLC (Non-small Cell Lung Cancer), HNSCC | Phase 1 | Recruiting | TwoStep Therapeutics, Inc. | 74 | 2026-09-02 | 2026-09-30 |
Carcinoma, Non-Small-Cell Lung (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Head and Neck Neoplasms (1) · Ovarian Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1) · Stomach Neoplasms (1)
TwoStep Therapeutics, Inc. (1)
United States (1)